<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier	Methods section/Paragraph 4	
name, catalogue number and RRID, if available.		

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR	Methods section/Paragraph 2	
supplier name, catalog number, clone number,		
OR RRID		
Primary cultures: Provide species, strain, sex of	Methods section/Paragraph 2	
origin, genetic modification status.		

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	This manuscript does not involve animal experiments.	n/a
Animal observed in or captured from the field: Provide species, sex and age where possible		n/a
Model organisms: Provide Accession number in repository (where relevant) OR RRID		n/a

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	This manuscript does not involve plants and microbes.	n/a
Microbes: provide species and strain, unique accession number if available, and source		n/a

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number	This manuscript does not involve any clinical trials.	n/a
for approval.		
Provide statement confirming informed consent obtained from study participants.		n/a
Report on age and sex for all study participants.		n/a

Design

6. 1	V (* 12	,
Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number OR cite DOI in manuscript.	This manuscript does not involve any clinical trials.	n/a
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-	All experimental protocols have been explained in	
by-step protocols are available.	detail in the methods section.	
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been	This manuscript does not involve any clinical trials.	
done, or if they were not carried out.		
Sample size determination		
Randomisation		
Blinding		
Inclusion/exclusion criteria		
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was	Methods section/Paragraph 6	
replicated in laboratory		
Define whether data describe technical or biological	Methods section/Paragraph 6	
replicates		
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of	This manuscript does not involve any clinical trials.	
authority granting ethics approval (IRB or equivalent	·	
committee(s), provide reference number for		
approval.		
Studies involving experimental animals: State details	This manuscript does not involve animal experiments.	
of authority granting ethics approval (IRB or		
equivalent committee(s), provide reference number		
for approval.		
Studies involving specimen and field samples: State if	This manuscript does not involve specimen and field	
relevant permits obtained, provide details of	samples.	
authority approving study; if none were required,		
explain why.		
Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern,	No	
state the authority granting approval and reference		
number for the regulatory approval		1

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is	Methods section/Paragraph 6	
excluded, and whether the criteria for exclusion were		
determined and specified in advance.		

Statistics	Yes (indicate where provided: section/paragraph)	n/a	ı
Describe statistical tests used and justify choice of	Methods section/Paragraph 6	1	l
tests.		1	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on		n/a
access.		
If data are publicly available, provide accession		n/a
number in repository or DOI or URL.		
If publicly available data are reused, provide		11/2
accession number in repository or DOI or URL, where		n/a
possible.		

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential	This manuscript does not involve newly generated	
for replicating the main findings of the study:	code and software.	
State whether the code or software is available.		
If code is publicly available, provide accession		
number in repository, or DOI or URL.		

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article information: https://dx.doi.org/10.21037/apm-21-1078